Immunologic Factor – Page 2

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

1 week ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal

2 weeks ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, CD38 Antigen, Clinical Trials, Global Licensing, Ichnos Glenmark, ISB, Multiple Myeloma, Neoplasms, Phase 1 (qualifier value), Trispecific Antibody

AbbVie; Ichnos Glenmark; ISB 2001; trispecific antibody; multiple myeloma; biotech deal; CD3; BCMA; CD38; Phase 1 clinical trial; global licensing; oncology

Alphabet’s Calico Strikes $596M Deal for Mabwell’s Anti-Aging Antibody

4 weeks ago talkbio0Tagged aging-related diseases, Alphabet, Antibodies, Biopharma, Calico, interleukin-11, Licensing, Mabwell

Calico; Alphabet; Mabwell; anti-aging; biotech; IL-11 antibody; 9MW3811; exclusive licensing; aging-related diseases; biopharma deal

RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

4 weeks ago talkbio0Tagged ACIP, Advisory Committees, anti-vaccine movement, Centers for Disease Control and Prevention (U.S.), Immunization, Influenza virus vaccine, Policy, Practice Experience, Respiratory syncytial virus, RFK Jr., thimerosal, Vaccines

RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices

Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

4 weeks ago talkbio0Tagged alliance, Autistic Disorder, Centers for Disease Control and Prevention (U.S.), Confirmation, Gavi Vaccine, Monarez, Nominee, Robert F. Kennedy Jr., Senate, Susan, Trump administration, Vaccine Safety, Vaccines

Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance

Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity

4 weeks ago talkbio0Tagged Approved, concerns, COVID19 (disease), delays, Intact, Interferes with, Novavax, political, Regulation of biological process, United States Food and Drug Administration, Vaccines

Novavax; FDA approval; COVID-19 vaccine; regulatory process; integrity concerns; delays; political interference

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

4 weeks ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

4 weeks ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

4 weeks ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

4 weeks ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy